TherapeuticsMD, Inc. Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables
TherapeuticsMD, Inc. (TXMD) had Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables of $29.30 million as of 2022-12-30, per its 10-K filed 2023-04-07.
Discontinued › Notes › Business Combination, Recognized Asset Acquired, Asset, Current
us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables · last filed 2023-04-07
- 2022-12-30: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables $29.30M.
| Period end | Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables |
|---|---|
| 2022-12-30 | $29.30M 10-K · filed 2023-04-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |